MOTS-C Research Findings

MOTS-c is a 16-amino-acid peptide encoded not in the cell’s nuclear genome but within a short reading frame in the mitochondrial 12S ribosomal RNA gene. This makes it one of a small, growing class of “mitochondrial-derived peptides” (MDPs) that appear to let mitochondria communicate directly with the rest of the cell during periods of metabolic stress [5].

Since its description in 2015, MOTS-c has been studied primarily for its role in energy metabolism. In cell and animal models, it appears to activate AMP-activated protein kinase (AMPK), a central cellular fuel sensor that gets switched on when energy is low, and this activation is linked to improved glucose uptake and insulin sensitivity [1,5]. MOTS-c has also been connected to NRF2, a transcription factor that governs the body’s antioxidant and cytoprotective response, suggesting a possible role in buffering oxidative stress [4,5]. Because circulating MOTS-c levels tend to decline with age and with worsening metabolic status in observational human studies, researchers have proposed it as both a potential biomarker of metabolic health and a candidate target for intervention [5].

It is important to be precise about what is established and what is hypothesized. The AMPK- and NRF2-related mechanisms described above come almost entirely from cell culture and animal experiments. Human data are largely correlational, not interventional.

Why the Liver? Understanding MASLD/MASH

The liver has become a major focus of metabolic peptide research because of the rising global burden of fatty liver disease. The condition once broadly called nonalcoholic fatty liver disease (NAFLD) has been reclassified by major hepatology societies as metabolic dysfunction-associated steatotic liver disease (MASLD), a name change meant to emphasize the metabolic drivers of the condition rather than simply the absence of alcohol use.

MASLD exists on a spectrum:

  • Steatosis — simple fat accumulation in liver cells, often reversible and not necessarily symptomatic.
  • MASH (metabolic dysfunction-associated steatohepatitis), formerly NASH — steatosis accompanied by liver cell injury and inflammation.
  • Fibrosis — scar tissue accumulation that, if it progresses, can lead to cirrhosis and its complications.

Because MOTS-c has been linked to insulin sensitivity, mitochondrial function, and antioxidant signaling—all pathways implicated in MASLD progression—researchers have begun testing whether it might influence steatosis, inflammation, or fibrosis directly.

Preclinical Evidence: Animal and Cell Studies

The 2015 Foundational Study

The original Cell Metabolism paper by Lee and colleagues established MOTS-c as a regulator of systemic metabolism. In mice, MOTS-c administration was associated with reduced diet-induced obesity and improved insulin resistance, with proposed signaling through AMPK [1]. This paper did not focus specifically on the liver, but it set the conceptual foundation—reduced adiposity and improved insulin sensitivity—that later liver-focused studies would build on.

The 2024 Cell Reports Study on NASH

A more directly liver-focused investigation came from Lu and colleagues, published in Cell Reports in 2024. Using a diet-induced NASH model in mice, the researchers tested both long-term preventive administration of MOTS-c (started before disease establishment) and short-term therapeutic administration (started after liver disease had developed). Both approaches were reported to alleviate NASH-diet-induced liver steatosis, along with other disease-associated changes in the liver [2]. The proposed mechanisms centered on MOTS-c’s known effects on mitochondrial function and metabolic signaling, consistent with the broader AMPK-related framework described above.

This study is notable because it distinguishes preventive from therapeutic timing—an important design feature for translational relevance—but it remains an animal study. The diet-induced mouse model of NASH captures some features of human disease but does not fully replicate human MASH pathology, genetics, or disease duration.

The 2025 Scientific Reports Study on Diabetic Liver Fibrosis

A 2025 study by Chen and colleagues, published in Scientific Reports, examined MOTS-c in the specific context of diabetic liver fibrosis. The researchers compared the effects of aerobic exercise, MOTS-c administration, and the combination of both in a model of type 2 diabetes-associated liver fibrosis. The paper proposes that MOTS-c “mimics exercise” in its liver-protective effects, acting through a Keap1–Nrf2–Smad2/3 pathway—linking antioxidant signaling (Keap1-Nrf2) to a pathway classically associated with fibrotic signaling (Smad2/3) [4]. This is a mechanistically interesting hypothesis connecting oxidative stress regulation to antifibrotic effects, but again, the evidence is preclinical.

Taken together, these three studies form a coherent but early-stage preclinical narrative: MOTS-c affects pathways relevant to fat accumulation, inflammation, oxidative stress, and fibrosis in animal models of liver disease.

Human Evidence: What We Actually Know

Human data on MOTS-c and the liver are considerably more limited and, crucially, observational rather than interventional. The most directly relevant human study is Kirik and colleagues’ 2023 paper in the European Review for Medical and Pharmacological Sciences, which examined circulating MOTS-c levels in patients with metabolic dysfunction-associated fatty liver disease (the terminology used at the time of publication). The study looked at how blood MOTS-c levels related to noninvasive fibrosis scores and components of metabolic syndrome [3].

This type of study can identify associations—for example, whether lower circulating MOTS-c correlates with higher fibrosis scores or worse metabolic parameters—but it cannot establish causation, and it certainly cannot demonstrate that raising MOTS-c levels (through exercise, lifestyle change, or exogenous administration) would improve liver outcomes in humans. Correlational biomarker studies are a common and valuable first step in human research, but they sit far earlier in the evidence hierarchy than randomized controlled trials.

As of this writing, there is no published randomized controlled trial testing exogenous MOTS-c administration for liver steatosis, MASH, or fibrosis in humans. The gap between promising mouse data and any human interventional liver evidence remains substantial.

Potential Liver-Related Benefits (Investigational Hypotheses)

Based on the preclinical literature described above, researchers have proposed several hypotheses about how MOTS-c might benefit the liver. Each of these should be understood as an investigational hypothesis supported by animal and cell data, not an established human benefit:

  • Reduced hepatic fat accumulation — suggested by the 2024 Cell Reports NASH model findings [2].
  • Improved insulin resistance and glucose handling, which could indirectly reduce drivers of fat accumulation in the liver, based on the foundational 2015 metabolic work [1].
  • Lower oxidative stress and inflammation, proposed through NRF2-related signaling [4,5].
  • Possible antifibrotic effects, suggested by the Keap1–Nrf2–Smad2/3 mechanism described in the 2025 diabetic fibrosis study [4].

None of these should be read as clinical claims. They represent plausible, biologically grounded directions for further research rather than demonstrated outcomes in patients.

Limitations and Safety

Several important limitations temper enthusiasm about MOTS-c as a liver therapeutic:

  • Animal-to-human translation is uncertain. Mouse models of NASH and diabetic fibrosis do not fully replicate human disease biology, and many promising rodent interventions have failed to translate to human benefit.
  • Pharmacokinetics and bioavailability in humans are not well characterized. Dosing, half-life, and tissue distribution of exogenously administered MOTS-c in people remain poorly defined in the public literature.
  • Assay variability affects circulating MOTS-c measurements across studies, complicating comparisons between papers and cohorts.
  • There is no standardized human dosing protocol validated for safety or efficacy.
  • Long-term human safety data are lacking. Existing human studies are observational and short in scope; chronic exogenous administration has not been systematically studied for safety.
  • Endogenous MOTS-c is not the same as injected or compounded MOTS-c products. The peptide naturally produced within mitochondria operates in a specific physiological context; unapproved compounded or injectable products marketed under this name have not undergone the regulatory review required to establish safety, purity, or effectiveness.

It bears stating plainly: MOTS-c is not an FDA-approved treatment for fatty liver disease, MASH, liver fibrosis, diabetes, or longevity. Readers should not self-administer research peptides and should not substitute them for clinician-directed, evidence-based care.

Conclusion

MOTS-c is a scientifically interesting mitochondrial peptide with a growing body of animal evidence suggesting relevance to liver fat accumulation, inflammation, and fibrosis. The mechanistic story—linking AMPK activation, NRF2 antioxidant signaling, and fibrotic pathways—is coherent and has motivated an active preclinical research program. However, the human evidence base remains limited to observational, correlational studies. No randomized controlled trial has yet tested MOTS-c as a liver treatment in people. The appropriate current framing is that MOTS-c represents a promising research target, not a validated therapy.

What Researchers Need to Learn Next

  • Randomized human trials testing exogenous MOTS-c (or MOTS-c–elevating interventions) against placebo, with liver-specific endpoints.
  • Validated, standardized assays for circulating MOTS-c to improve comparability across studies.
  • Dose-ranging studies in humans to establish safety margins and pharmacokinetics.
  • Liver imaging and biopsy-based endpoints (such as MRI-PDFF for fat content or histological fibrosis staging) rather than reliance on noninvasive scores alone.
  • Long-term safety monitoring, particularly given the peptide’s broad signaling roles across metabolic, muscular, and potentially neurological systems.
Chatbot
Chatbot

Your Guide to Good Health and Longevity